Abliva AB is a Swedish company that is active in pharmaceutical development. It develops medicines for the treatment of primary mitochondrial diseases. These congenital, rare and often very severe diseases occur when the cell's energy provider, the mitochondria, does not function properly. The portfolio includes projects at different stages and ranges from the early discovery phase to the clinical phase.
Quote | Neurovive Pharm Ab Ord (OTCMKTS:NEVPF)
Last: | $0.01 |
---|---|
Change Percent: | 100.0% |
Open: | $0 |
Close: | $0.01 |
High: | $0 |
Low: | $0 |
Volume: | 210,000 |
Last Trade Date Time: | 12/31/1969 07:00:00 pm |
News | Neurovive Pharm Ab Ord (OTCMKTS:NEVPF)
- Independent committee confirms FALCON study is powered for potential success with both alternative endpoints passing futility- -Committee confirms strong safety profile of KL1333- - Abliva to host conference call and webcast on Friday 19 July at 4:30 pm CET / 10:30 am ...
LUND, Sweden, May 13, 2024 (GLOBE NEWSWIRE) -- Abliva AB (Nasdaq Stockholm: ABLI), a clinical-stage company developing drugs for the treatment of rare and severe primary mitochondrial disease, today announced that it will host a virtual KOL event on Tuesday, May 21, 2024 at 10:00 AM ET / 4:00 PM ...
Message Board Posts | Neurovive Pharm Ab Ord (OTCMKTS:NEVPF)
Subject | By | Source | When |
---|---|---|---|
Hi. I was wandering if you were invested | Chrisny73 | investorshub | 05/19/2021 5:08:32 PM |
NeuroVive Pharmaceutical AB changed to Abliva AB | Renee | investorshub | 05/29/2020 1:06:19 AM |
Just might be...thanks for the alert Chrisny73... GL...$NEVPF | Golden Cross | investorshub | 02/19/2020 7:02:34 PM |
Looks like a buying opportunity here | Chrisny73 | investorshub | 02/19/2020 6:25:00 PM |
$NEVPF Tier_Change: OTCQX International to Pink Current | Golden Cross | investorshub | 01/02/2020 7:36:10 AM |
News, Short Squeeze, Breakout and More Instantly...
Neurovive Pharm Ab Ord Company Name:
NEVPF Stock Symbol:
OTCMKTS Market:
Neurovive Pharm Ab Ord Website:
- Independent committee confirms FALCON study is powered for potential success with both alternative endpoints passing futility- -Committee confirms strong safety profile of KL1333- - Abliva to host conference call and webcast on Friday 19 July at 4:30 pm CET / 10:30 am ...
LUND, Sweden, May 13, 2024 (GLOBE NEWSWIRE) -- Abliva AB (Nasdaq Stockholm: ABLI), a clinical-stage company developing drugs for the treatment of rare and severe primary mitochondrial disease, today announced that it will host a virtual KOL event on Tuesday, May 21, 2024 at 10:00 AM ET / 4:00 PM ...
Abliva AB (publ) (NEVPF) is expected to report for Q4 2023